February 25, 2008 - Akesis Pharmaceuticals, Inc. (OTC/BB: AKES), an emerging diabetes drug-development company, announced it has initiated dosing of patients in its placebo controlled Phase IIa trial for AKP-020, a novel vanadium compound, to test its safety and efficacy in patients with Type 2 Diabetes."We are pleased to have reached this Phase IIa milestone," said Jay Lichter, president and chief executive officer of Akesis. "We are on track to complete enrollment and dosing according to schedule and anticipate announcing results when they become available."
dgd Research of San Antonio, TX, now a member of Cetero Research, is conducting the Phase IIa, controlled U.S. clinical trial. The trial will enroll a total of 21 diabetic patients at a single site measuring efficacy (using the gold-standard euglycemic-hyperinsulinemic clamping procedure), as well as pharmacokinetic parameters, safety and tolerability of AKP-020 in diabetic patients... Akesis Pharmaceuticals' Press Release -
